Literature DB >> 8144768

Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty.

J J Ferguson1, K G Dougherty, C M Gaos, H S Bush, K C Marsh, D R Leachman.   

Abstract

OBJECTIVES: The purpose of this study was to determine whether a low procedural activated coagulation time is associated with a high rate of in-hospital complications and to identify whether there is an activated coagulation time range that may be associated with a low rate of complications.
BACKGROUND: In recent years the activated coagulation time has come into widespread use for monitoring anticoagulation in the catheterization laboratory. However, considerable controversy exists as to the standards by which to judge "adequate" anticoagulation for interventional procedures.
METHODS: From a total of 1,469 consecutive patients with percutaneous transluminal coronary angioplasty, we retrospectively identified 103 (Group I, 7% of the overall population) with major complications of death or emergency or urgent coronary artery bypass graft surgery and compared them with 400 patients without complications (Group II). Group I patients had more high risk clinical characteristics, such as type B and C lesions, class III and IV angina, recent myocardial infarction and recent thrombolytic treatment. Activated coagulation times were compared between Groups I and II at baseline, after administration of 10,000 U of heparin and at the end of the procedure.
RESULTS: There were no differences in baseline activated coagulation times between Groups I and II. Group I had significantly lower activated coagulation times after heparin therapy and at the end of the procedure: 61% < 250 s, 20% between 250 and 275 s, 11% between 275 and 300 s and 8% > 300 s; 279 of Group II had activated coagulation times 27% < 250 s, 17% between 250 and 275 s, 35% between 275 and 300 s and 21% > 300 s (p < 0.0001). Complications occurred in all patients with final activated coagulation times < 250 s but in only 0.3% of patients with final activated coagulation times > 300 s.
CONCLUSIONS: A diminished activated coagulation time response to an initial bolus of heparin is associated with major in-hospital complications after coronary angioplasty, although patients with complications did have a higher risk before the procedure. It remains to be determined whether there is an ideal "target" activated coagulation time for interventional procedures.

Entities:  

Mesh:

Year:  1994        PMID: 8144768     DOI: 10.1016/0735-1097(94)90590-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Monitoring Anticoagulation During Percutaneous Coronary Interventions.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Antithrombotic Therapy during Percutaneous Coronary Intervention.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 3.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

4.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

5.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

6.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 7.  A guide to drug use during percutaneous coronary intervention.

Authors:  Joseph K Choo; John J Young; Dean J Kereiakes
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.

Authors:  H M Hussein; A L Georgiadis; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

Review 9.  Heparin dose during percutaneous coronary intervention: how low dare we go?

Authors:  G Niccoli; A P Banning
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 10.  Unfractionated versus fractionated heparin for percutaneous coronary intervention.

Authors:  Heidar Arjomand; Satish K Surabhi; Marc Cohen
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.